Navigation Links
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
Date:1/14/2014

advanced breast cancer, particularly for patients with HER2-negative breast cancer and triple-negative breast cancer." 

Positive Phase 2 data for NKTR-102 were recently published in Lancet Oncology in November 2013. (1)  Etirinotecan pegol achieved a confirmed objective response rate by RECIST of 29 percent. NKTR-102 demonstrated a high clinical benefit rate (CR+PR+SD greater than six months) of 37 percent (13/35) in the 14-day group and 49 percent (17/35) in the 21-day group. Six patients experienced 100 percent resolution of all target lesions, with two complete RECIST responses and four near-complete responses.
Patients treated exhibited low rates of alopecia, neuropathy and neutropenia, which are significant adverse events associated with existing breast cancer therapies. Side effects were generally manageable; the most common Grade 3 toxicity was diarrhea (17-23%) typically occurring after three months of therapy.

About the BEACON StudyBEACON is a Phase 3, open-label, randomized, multicenter study of NKTR-102 which enrolled 852 women with locally recurrent or metastatic breast cancer, who have previously been treated with ATC. The trial is being conducted at approximately 150 sites worldwide including North America, Western Europe, Russia and the Republic of Korea.  Nearly half of the patients enrolled in BEACON were located in North America.  Patients were randomized on a 1:1 basis to receive 145 mg/m2 of single-agent NKTR-102 once every three weeks or a single agent of physician's choice.  The physician's choice agents include: ixabepilone, vinorelbine, gemcitabine, eribulin, or a taxane.  Randomization was stratified by geographic region, prior use of eribulin and receptor status. 

The primary endpoint of the BEACON study is overall survival; secondary endpoints include progression-free survival, objective tumor response
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. CAS REGISTRY(SM) surpasses 75 million small molecules
6. WuXi Manufacturing Facility Passes FDA Inspection
7. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
8. Emotivs Brainwear Technology To Track Cognitive Health Surpasses $1M Kickstarter Stretch Goal
9. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
10. French Man with SynCardia Total Artificial Heart Surpasses Two Years of Support
11. NABPs .PHARMACY Proposal Passes Initial ICANN Evaluation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
(Date:12/24/2014)... Ohio , Dec. 23, 2014   ... treatment decision support to healthcare providers for behavioral ... it has secured $30 million in equity financing ... Virginia C. Drosos , President and Chief Executive ... clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 2011 The CAQH® Universal Provider Datasource® (UPD®) ... as the go-to resource for complete and reliable ...  Three out of five licensed and practicing physicians ... service. About 7,000 additional providers are registering each ...
... 2011 Instrumentation Laboratory (IL) today announced the appointment ... effective May 1, 2011.  Mr. Benet began his career ... Vice President of Worldwide Marketing, Sales and Service.   ... Josep Manent who served as CEO since 1999.  Under ...
Cached Medicine Technology:900,000 Healthcare Providers Now Part of CAQH Universal Provider Datasource 2900,000 Healthcare Providers Now Part of CAQH Universal Provider Datasource 3Instrumentation Laboratory Appoints Ramon E. Benet New Chief Executive Officer 2
(Date:12/24/2014)... 24, 2014 Verde Pointe Dental Associates 2014 ... "Last years homemade Christmas sweater lit up, but this ... 2014 winner is Tandy Wilson for the second year in ... says Kirk Kimmerling DDS. "She took pictures of the entire ... sweater." , "Every year I enjoy stopping by ...
(Date:12/24/2014)... “ Relax Melodies ” was featured on NewsWatch ... latest and coolest mobile applications on the iOS, Android, ... and host of NewsWatch, conducted the app review and ... they can fall asleep. , According to the National ... some sort of difficulty sleeping. Since that’s a huge ...
(Date:12/24/2014)... California (PRWEB) December 24, 2014 Final ... of the ProDenoise from Pixel Film Studios. , “The ProDenoise ... or grain in their footage,” said Christina Austin, CEO of ... in any Final Cut Pro X editors toolbox.” , Final ... noise or grain in their footage with ProDenoise from Pixel ...
(Date:12/24/2014)... Kathleen Doheny HealthDay Reporter ... diet of fast food might hurt your child in the ... fast food in fifth grade lagged behind by eighth grade, ... than 8,500 U.S. students. "The largest effects were found ... said study leader Kelly Purtell, assistant professor of human sciences ...
(Date:12/24/2014)... 2014 (HealthDay News) -- Longer and colder body cooling does ... brain damage from a lack of oxygen, a new study ... with this condition -- called hypoxic ischemic encephalopathy -- can ... Celsius (92.3 Fahrenheit) for 72 hours, experts say. Research ... of animals, so this study examined if the same would ...
Breaking Medicine News(10 mins):Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2Health News:An Application to Help with Insomnia was Featured on NewsWatch Television on December 19, 2014 2Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2Health News:Can Fast Food Hinder Learning in Kids? 2Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2
... shows young donors experience a lower rate of adverse reactions ... , LAKE ZURICH, Ill., June 23 Fenwal Inc. ... Richard J. Benjamin, M.D., Ph.D., chief medical officer of the ... relative safety of automated two-unit red cell procedures and manual ...
... Healthcare, Inc. (PDHI) launches the ConXus Profile Third-Party Health ... merge historical data from third-party HRAs with data collected ... may be reluctant to switch their current HRA data ... health information accumulated over time. PDHI has developed ...
... say , TUESDAY, June 23 (HealthDay News) -- Women ... developing brain lesions, a new study has found. , Whether ... cognition, however, remains unknown, the researchers added. , "Migraine used ... occurred, but these data suggest that there may be tissue ...
... to maintain a healthy weight, , TUESDAY, June 23 (HealthDay ... increases the risk for pancreatic cancer, and obesity in middle ... new study finds. , Pancreatic cancer is the fourth leading ... United States. As the number of people who are overweight ...
... ... threaten financial and emotional health -- and your life, says cancer survivor Jo ... of health insurers. She thought the healthcare system might have changed since she ... serious condition. Godfrey knows she is not alone, and she is ...
... ... needs of our nation,s over-the-road drivers and will showcase their efforts at The Great West ... ... Lifeclinic International, Inc., the world,s leading manufacturer and distributor of automated blood pressure monitors ...
Cached Medicine News:Health News:Fenwal to Host Webinar on the Safety of 2-Unit Red Cell Collections From Young Donors 2Health News:Fenwal to Host Webinar on the Safety of 2-Unit Red Cell Collections From Young Donors 3Health News:PDHI Launches ConXus Profile Third-Party Health Risk Assessment Data-Load Process 2Health News:Migraine With Aura May Lead to Brain Lesions 2Health News:Migraine With Aura May Lead to Brain Lesions 3Health News:Obesity While Young Boosts Pancreatic Cancer Risk 2Health News:Obesity While Young Boosts Pancreatic Cancer Risk 3Health News:Insurance May Be Hazardous to Your Health: "They Figured It Was Cheaper to Kill Me" 2Health News:Insurance May Be Hazardous to Your Health: "They Figured It Was Cheaper to Kill Me" 3Health News:Insurance May Be Hazardous to Your Health: "They Figured It Was Cheaper to Kill Me" 4Health News:Lifeclinic Teams Up With Trucking Industry to Promote Health and Wellness to Over-the-Road Professionals 2Health News:Lifeclinic Teams Up With Trucking Industry to Promote Health and Wellness to Over-the-Road Professionals 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: